REMS For Obesity Drugs May Need More Specifics After Qnexa Advisory Panel

Providing the details of a risk management strategy would aid sponsors in their quest for a positive response to weight-loss drugs from FDA's Endocrinologic and Metabolic Drugs Advisory Committee, the panel indicated July 15 in its review of Vivus's Qnexa